Quick Answer
Design Therapeutics, Inc. reported Operating Income Loss of -$79.47 million for the year ending 2025.
- Design Therapeutics, Inc. showed a decrease of -27.4% in Operating Income Loss from 2024 to 2025.
- This data is from Design Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$623.0 thousand | Q2 2020: -$1.46 million | Q3 2020: -$2.38 million | Q1 2021: -$5.68 million | Q2 2021: -$7.69 million | Q3 2021: -$11.34 million | Q1 2022: -$13.37 million | Q2 2022: -$15.64 million | Q3 2022: -$19.19 million | Q1 2023: -$21.65 million | Q2 2023: -$22.60 million | Q3 2023: -$18.82 million | Q1 2024: -$14.40 million | Q2 2024: -$15.04 million | Q3 2024: -$16.25 million | Q1 2025: -$20.42 million | Q2 2025: -$21.57 million | Q3 2025: -$19.31 million.
- Over the full 6 years of available data (2020 to 2025), Design Therapeutics, Inc.'s Operating Income Loss has declined by 854.0%.
- Historical annual values: Fiscal year 2025: -$79.47 million | Fiscal year 2024: -$62.38 million | Fiscal year 2023: -$78.19 million | Fiscal year 2022: -$67.59 million | Fiscal year 2021: -$35.83 million | Fiscal year 2020: -$8.33 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: